Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2023 | HER2-targeting ADCs for urothelial carcinoma

Daniel Petrylak • 3 Jun 2023
ASCO 2023
Genitourinary Cancer Urothelial Carcinoma Antibodies Enfortumab

Daniel Petrylak, MD, Yale School of Medicine, New Haven, CT, discusses HER2 as an antibody-drug conjugate (ADC) target for urothelial carcinoma (UC). This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Daniel Petrylak

0:43
Current developments in FGFR inhibitors for urothelial cancer
Daniel Petrylak • 3 Jun 2023
1:59
How can we best sequence novel treatments in urothelial cancer?
Daniel Petrylak • 3 Jun 2023
1:04
THOR: erdafitinib in advanced or metastatic urothelial cancer and FGFR alterations
Daniel Petrylak • 3 Jun 2023
1:30
VBIR vaccine shows promise in prostate cancer: Phase I trial results and immunotherapy potential
Daniel Petrylak • 3 Jun 2023

Related Videos

4:05
Evaluating triplet therapy in metastatic hormone sensitive prostate cancer
Nick James • 24 Apr 2024
10:42
Management of prostate cancer from the patient perspective
David Matheson • 11 Apr 2024
2:26
Prognostic factors of renal cell cancer in elderly patients
Teemu Murtola • 9 Apr 2024
2:44
The effect of hypoxia on lipid metabolism and prostate cancer tumor growth
Teemu Murtola • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals